wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26741277-5A40F39D-BEF1-47D9-B7C6-700A1A2DB766
Q26741277-5A40F39D-BEF1-47D9-B7C6-700A1A2DB766
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26741277-5A40F39D-BEF1-47D9-B7C6-700A1A2DB766
A Perspective of Immunotherapy for Prostate Cancer
P2860
Q26741277-5A40F39D-BEF1-47D9-B7C6-700A1A2DB766
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26741277-5A40F39D-BEF1-47D9-B7C6-700A1A2DB766
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f7d3c231a378f9306cfb6bd023f9d975d9ad180d
P2860
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.